NMUR1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL2632647	0.84	16/20
SCHEMBL2625064	0.64	16/20
SCHEMBL2633390	0.60	16/20
SCHEMBL2625082	0.59	16/20
SCHEMBL2628471	0.57	16/20
SCHEMBL2628468	0.53	16/20
SCHEMBL2632769	0.73	15/20
SCHEMBL8808113	0.70	15/20
SCHEMBL8808129	0.70	15/20
SCHEMBL2628463	0.63	15/20
SCHEMBL10078439	0.56	15/20
SCHEMBL2628467	0.55	15/20
SCHEMBL2628462	0.53	15/20
SCHEMBL2632668	0.73	14/20
SCHEMBL5498560	0.65	14/20
SCHEMBL2628482	0.56	14/20
SCHEMBL2625080	0.55	14/20
SCHEMBL2628478	0.49	14/20
SCHEMBL10774369	0.58	13/20
SCHEMBL2628464	0.54	13/20

Clinical trials — most relevant to NMUR1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Mechanisms of Capsaicin Treatment in Idiopathic Rhinitis Patients and Controls	PHASE4	COMPLETED
Interaction Between Magnesium and Neostigmine or Sugammadex for the Reversal of a Rocuronium-induced Neuromuscular Block	PHASE4	COMPLETED
Intravenous Ketorolac and Metoclopramide for Pediatric Migraine in the Emergency Department	PHASE4	COMPLETED
The Role of Negr1 In Modulating Neuroplasticity in Major Depression (RONIN)	PHASE4	UNKNOWN
OnabotulinumtoxinA (onaBoNT-A) Versus Oral Oxybutynin ER	PHASE3	UNKNOWN
Improving Outcomes in Neonatal Abstinence Syndrome	PHASE3	COMPLETED
A Series of Pilot Studies to Evaluate the haemoDynamic and mEtabolic Effects oF apelIn aNd rElaxin	PHASE2	UNKNOWN
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of Subcutaneous AGX-201 for Migraine Prophylaxis	PHASE2	UNKNOWN
Safety and Efficacy of the PAINLESS Nerve Growth Factor CHF6467 in Optic Pathway Glioma (OPG)	PHASE2	ACTIVE_NOT_RECRUITING
Treatment of Unresectable Hepatocellular Cancer With Opioid Growth Factor	PHASE1	COMPLETED
Neuroimmune Effects of Opioid Administration	PHASE1	COMPLETED
Brain Networks and Addiction Susceptibility	PHASE1	COMPLETED
PET Brain and Whole Body Distribution Studies for Nociceptin/Orphanin FQ Peptide (NOP) Receptor Using [11C]NOP-1A	EARLY_PHASE1	COMPLETED
Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine	EARLY_PHASE1	COMPLETED
Selective Activation of the Adrenomedullin Receptors in Migraine	nan	NOT_YET_RECRUITING
Reversal of Neuromuscular Blockade in Thoracic Surgical Patients	nan	COMPLETED
Common Noradrenergic Mechanisms in Parkinson´s Disease and L-DOPA Induced Dyskinesia	nan	UNKNOWN
Changes of microRNA Expression in Obstructive and Neurogenic Bladder Dysfunction	nan	COMPLETED
Effect of Polymorphisms in the Adenosine a2a Receptor Gene and AMPD2 Gene on Adenosine-Induced Vasodilation and Reactive Hyperemia	nan	COMPLETED
Changes in Skin Innervation of Neurologically Asymptomatic Type 2 Diabetic Patients: the Correlation With the Diabetic Parameters and Neurotrophins.	nan	UNKNOWN
mGluR5 Imaging in ALS Using PET	nan	UNKNOWN
Preemptive Oral Gabapentin and Tramadol on Postoperative Pain After Knee Arthroscopy	nan	COMPLETED
Exploring the Genetics of Neuropathic Pain	nan	RECRUITING
Searching for Novel Therapeutic Approaches in Migraine Patients Resistant to Treatments	nan	RECRUITING
Urinary NGF as A Biomarker for Acute Bacterial Cystitis	nan	COMPLETED
Gene-STEPS: Shortening Time of Evaluation in Paediatric Epilepsy Services	nan	UNKNOWN
The Role of Urinary ATP in the Diagnosis, Treatment, and Follow-up of Children With Overactive Bladder	nan	COMPLETED
Association of Urine BDNF and NGF With Lower Urinary System Parameters	nan	RECRUITING
A Brain Imaging Study Into Nicotine Induced Dopamine Release in Cigarette Smokers.	nan	UNKNOWN
Investigation of Brain Mechanisms Involved in the Urinary Continence Mechanism Associated With Aging	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a NMUR1 binder may also engage these)

Protein	Name	Similarity
O55040	—	0.995	O55040 →
Q9JJI5	—	0.992	Q9JJI5 →
Q63384	—	0.986	Q63384 →
P70310	—	0.986	P70310 →
NTSR1	Neurotensin receptor type 1	0.984	landscape →
NTSR2	Neurotensin receptor type 2	0.984	landscape →
O08726	—	0.980	O08726 →
Q8BZ39	—	0.980	Q8BZ39 →
Q9ESQ4	—	0.979	Q9ESQ4 →
GALR2	Galanin receptor type 2	0.979	landscape →
O88319	—	0.978	O88319 →
P20789	—	0.978	P20789 →
Q58CW4	—	0.976	Q58CW4 →
O88854	—	0.976	O88854 →
P30729	—	0.976	P30729 →
P11617	—	0.975	P11617 →
P30935	—	0.974	P30935 →
NMUR2	Neuromedin-U receptor 2	0.973	landscape →
Q7TQN7	—	0.973	Q7TQN7 →
P30936	—	0.972	P30936 →
Q5YKK9	—	0.972	Q5YKK9 →
LPAR2	Lysophosphatidic acid receptor 2	0.972	landscape →
Q7TQP2	—	0.972	Q7TQP2 →
Q95252	—	0.972	Q95252 →
P51436	—	0.972	P51436 →
ADRB3	Beta-3 adrenergic receptor	0.971	landscape →
Q5IS72	—	0.971	Q5IS72 →
HTR6	5-hydroxytryptamine receptor 6	0.971	landscape →
Q9XT58	—	0.971	Q9XT58 →
Q60613	—	0.971	Q60613 →